Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PTC Therapeutics, Inc. - Common Stock
(NQ:
PTCT
)
76.74
+0.78 (+1.03%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PTC Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?
↗
May 05, 2025
PTC518 showed reduced HTT protein and plasma NfL levels in Huntington's patients, with signals of clinical benefit across multiple functional scales.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 05, 2025
Via
Benzinga
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
↗
May 05, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
May 05, 2025
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via
Chartmill
Earnings Scheduled For February 27, 2025
↗
February 27, 2025
Via
Benzinga
Earnings Preview For PTC Therapeutics
↗
November 06, 2024
Via
Benzinga
These stocks that are showing activity before the opening bell on Monday.
↗
May 05, 2025
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Via
Chartmill
9 Health Care Stocks With Whale Alerts In Today's Session
↗
April 22, 2025
Via
Benzinga
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder
↗
March 28, 2025
PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review.
Via
Benzinga
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July
↗
March 20, 2025
PTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025.
Via
Benzinga
This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
↗
March 11, 2025
Via
Benzinga
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
↗
December 10, 2024
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.
Via
Investor's Business Daily
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
↗
December 06, 2024
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.
Via
Benzinga
Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
December 03, 2024
Via
Benzinga
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
↗
December 02, 2024
PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties.
Via
Benzinga
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
↗
December 02, 2024
Via
Benzinga
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
↗
December 02, 2024
The deal focuses on the company's treatment for Huntington's disease.
Via
Investor's Business Daily
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
↗
November 27, 2024
PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including Huntington's and PKU programs.
Via
Benzinga
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
↗
November 14, 2024
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment.
Via
Benzinga
3 Top Stocks That Could Still Rocket Higher in 2024
↗
October 04, 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
Via
The Motley Fool
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
↗
August 19, 2024
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.
Via
Investor's Business Daily
PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 10, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
June 28, 2024
Via
Benzinga
PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
↗
June 28, 2024
The company plans to ask for another re-examination for its drug in Europe.
Via
Investor's Business Daily
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
↗
June 21, 2024
Via
Benzinga
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
↗
June 20, 2024
PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program.
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
↗
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
May 20, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
